RxDoctor Payments Data

Jeffrey White

Psychiatric/Mental Health · Delhi, LANPI 1033559174

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.6% of the total across 450 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 13.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,373, 2.2 times the $1,090 reported in 2021. Among psychiatric/mental health clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,687in general payments, 2019–2025

Across 450 payments — averaging $17.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Alkermes, Inc.$1K
  • Indivior Inc.$749
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$595
  • Axsome Therapeutics, Inc.$561
  • Otsuka America Pharmaceutical, Inc.$552
  • plus $3K from 13 others

What the payments were for

  • Food & beverage$7,57799%
  • Education$1101%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,687 in reported general payments places this provider in the 90th percentile of 615 psychiatric/mental health providers in Louisiana.

See all psychiatric/mental health providers in Louisiana

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole42$66,725
VraylarCariprazine Hcl43$63,634
Invega SustennaPaliperidone Palmitate18$54,104
Abilify MaintenaAripiprazole11$32,030
AuvelityDextromethorphan Hbr/Bupropion19$19,110
TrintellixVortioxetine Hydrobromide33$15,782
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl51$12,579
Venlafaxine Hcl ErVenlafaxine Hcl124$2,482
Thiothixene13$1,752
Divalproex Sodium ErDivalproex Sodium26$1,639
Aripiprazole94$1,401
Olanzapine41$1,323
Quetiapine Fumarate106$1,002
Oxcarbazepine42$991
Fluoxetine Hcl95$971

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$552$98,75653 claims
AbbVieVraylar$1,025$63,63443 claims
Johnson & JohnsonInvega Sustenna$464$54,10418 claims
Axsome Therapeutics, Inc.Auvelity$561$19,11019 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$147$15,78233 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 615 psychiatric/mental health providers in Louisiana.

Other psychiatric/mental health in Delhi

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →